Prevalence of HIV-1 drug resistance in treated patients with viral load &gt;50&nbsp;copies/mL: a 2014 French nationwide study

Assoumou, L; Charpentier, C; Recordon-Pinson, P; Grudé, M; Pallier, C; Morand-Joubert, L; Fafi-Kremer, S; Krivine, A; Montes, B; Ferré, V; Bouvier-Alias, M; Plantier, J-C; Izopet, J; Trabaud, M-A; Yerly Ferrillo, Sabine; Dufayard, J; Alloui, C; Courdavault, L; Le Guillou-Guillemette, H; Maillard, Anne; Amiel, C; Vabret, A; Roussel, C; Vallet, Simon-Ulysse; Guinard, J; Mirand, A; Beby-Defaux, A; Barin, F; Allardet-Servent, A; Ait-Namane, R; Wirden, M; Delaugerre, C; Calvez, V; Chaix, M-L; Descamps, D; Reigadas, S

doi:10.1093/jac/dkx042

Scientific article

English

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

Published inJournal of Antimicrobial Chemotherapy, vol. 72, no. 6, p. 1769-1773

Publication date2017

Abstract

Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance.

Affiliation entities

Not a UNIGE publication

Citation (ISO format)

ASSOUMOU, L et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. In: Journal of Antimicrobial Chemotherapy, 2017, vol. 72, n° 6, p. 1769–1773. doi: 10.1093/jac/dkx042

Article (Published version)

Identifiers

PID : unige:99803
DOI : 10.1093/jac/dkx042
PMID : 28333232

Journal ISSN0305-7453

488views

2downloads

Creation30/10/2017 11:08:00

First validation30/10/2017 11:08:00

Update15/03/2023 02:30:19

Status update15/03/2023 02:30:17

Last indexation31/10/2024 08:52:12

Archive ouverte UNIGE

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance.

Technical informations